YMAB•benzinga•
Oppenheimer Initiates Coverage On Y-mAbs Therapeutics with Outperform Rating, Announces Price Target of $23
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 18, 2024 by benzinga